Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chromophobe Renal Cell Carcinoma: early-phase trial registry
4 of 9 indexed Chromophobe Renal Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Chromophobe Renal Cell Carcinoma: 9 US clinical trials tracked, 4 recruiting.
Chromophobe Renal Cell Carcinoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition chromophobe-renal-cell-carcinoma
OPEN 4 | RECR 44% | LATE 0 | EARLY 7 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Chromophobe Renal Cell Carcinoma lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chromophobe Renal Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chromophobe Renal Cell Carcinoma is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Chromophobe Renal Cell Carcinoma research.
National Cancer Institute (NCI) accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Chromophobe Renal Cell Carcinoma enrolment sits around 67 participants.
Median target enrolment is 67 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.
-
Chromophobe Renal Cell Carcinoma research is mostly interventional.
8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
University of Texas Southwestern Medical Center
NCT04623502
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
NCT03866382
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility
NCT06805825
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Dana-Farber Cancer Institute
NCT06318871
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
Mayo Clinic
NCT06339138
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
NCT04071223
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Bradley A. McGregor, MD
NCT04413123
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT03635892
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT03541902
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Chromophobe Renal Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chromophobe Renal Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chromophobe Renal Cell Carcinoma page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Chromophobe Renal Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Chromophobe Renal Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chromophobe Renal Cell Carcinoma condition card totals 9 registered trials; most-linked intervention Cabozantinib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.